J1 | Cannabis Strain Review & Effects
Skunk #1 x Jack Herer
J1 is a hybrid-leaning sativa strain (Skunk #1 x Jack Herer) with THC levels of 18-24%. It features a Terpinolene-dominant terpene profile and is known for relaxed and happy. Best used during the evening.
THC
18-24%
CBD
0-1%
Best Time
Primary Effects
Flavor Notes
Earthy, Sweet, Herbal
Aroma
Earthy aroma with sweet and pungent notes
Research Sources
27 peer-reviewed studies
Verified Via
PubMed / DOI
Evidence
Research-Backed
Updated
December 2025
What is J1?
J1 is a hybrid-leaning sativa strain (Skunk #1 x Jack Herer) with THC levels of 18-24%. It features a Terpinolene-dominant terpene profile and is known for relaxed and happy. Best used during the evening.
About J1 Strain
J1 is a sativa-dominant hybrid cannabis strain created by crossing Skunk #1 x Jack Herer. Testing at 18-24% THC, J1 offers moderate to strong potency suitable for regular cannabis consumers.
Users of J1 commonly report feeling relaxed, happy, euphoric. The experience typically begins with an uplifting cerebral rush that sparks creativity and mental clarity. As the high develops, many users find themselves more talkative and socially engaged. Best enjoyed in the evening, this strain helps transition from the day's activities into a more relaxed state.
Medical cannabis patients frequently turn to J1 for relief from stress, anxiety, chronic pain. Terpinolene's presence adds uplifting qualities while potentially offering antioxidant and sedative properties at higher doses.
Due to its moderate-to-high potency, J1 is best suited for experienced cannabis consumers. New users should approach with caution, starting with a very small dose and waiting to assess effects before consuming more. Common side effects may include dry mouth, dry eyes. Staying well-hydrated and having snacks on hand can help minimize discomfort.
The aroma of J1 is characterized by earthy, sweet, pungent notes that create a distinctive sensory profile. On the palate, expect earthy, sweet, herbal flavors that develop throughout each session. The terpinolene-dominant terpene profile is largely responsible for these aromatic and flavor characteristics, contributing to the entourage effect that shapes the overall experience.
Related Reading
Commonly Used For
Patients often seek J1 for relief from the following conditions:
Note: These are commonly reported uses based on patient experiences. Individual results may vary. Always consult with a healthcare provider to determine if medical cannabis is appropriate for your specific condition.
Potential Side Effects
Be aware of these commonly reported side effects when using J1:
How to minimize side effects
- Start with a low dose, especially if new to cannabis
- Stay hydrated before, during, and after use
- Use in a comfortable, familiar environment
- Avoid mixing with alcohol or other substances
Terpene Profile
Primary research: Sedative (in isolation)
Concentration Levels
Cannabinoid Profile
Therapeutic Profile Matches
Based on J1's terpene and cannabinoid profile, it may be well-suited for these therapeutic applications:
muscle spasms
- High beta-caryophyllene content supports muscle spasms & spasticity
- Best used evening, aligning with condition needs
migraines
- High beta-caryophyllene content supports migraines & headaches
- thc dominant ratio matches profile
- Best used evening, aligning with condition needs
epilepsy
- High beta-caryophyllene content supports epilepsy & seizures
- Best used evening, aligning with condition needs
ptsd
- High beta-caryophyllene content supports ptsd & trauma
- thc dominant ratio matches profile
- Best used evening, aligning with condition needs
multiple sclerosis
- High beta-caryophyllene content supports multiple sclerosis
- Best used evening, aligning with condition needs
Match scores are theoretical
These scores are based on terpene/cannabinoid research and do not guarantee specific effects. Individual responses vary significantly. Always consult a healthcare provider.
- 1
Ito K, Ito M. The sedative effect of inhaled terpinolene in mice and its structure-activity relationships Journal of Natural Medicines. 2013
Terpinolene prolonged sleep time in mice.
- 2
Grassmann J, et al. The monoterpene terpinolene from the oil of Pinus mugo L. in concert with alpha-tocopherol and beta-carotene effectively prevents oxidation of LDL Phytomedicine. 2005
Terpinolene showed strong antioxidant activity.
- 3
Gertsch J, et al. β-Caryophyllene is a dietary cannabinoid Proceedings of the National Academy of Sciences. 2008
Landmark paper: BCP directly activates CB2 receptors.
- 4
Klauke AL, et al. The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain European Journal of Pain. 2014
Showed dual mechanism for neuropathic pain relief.
- 5
Bahi A, et al. β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice Physiology & Behavior. 2014
BCP reduced anxiety via CB2 receptor activation.
- 6
Horvath B, et al. β-Caryophyllene ameliorates cisplatin-induced nephrotoxicity in a cannabinoid 2 receptor-dependent manner Free Radical Biology and Medicine. 2012
BCP reduced inflammation markers and oxidative stress.
- 7
Tambe Y, et al. Gastric cytoprotection of the non-steroidal anti-inflammatory sesquiterpene, beta-caryophyllene Planta Medica. 1996
BCP protected gastric mucosa in ulcer models.
- 8
Surendran S, et al. Myrcene-What Are the Potential Health Benefits of This Flavouring and Aroma Agent? Frontiers in Nutrition. 2021
Comprehensive review: β-myrcene may potentiate the anti-nociceptive properties of cannabinoids.
- 9
Johnson MB, et al. The Effects of β-myrcene on Simulated Driving and Divided Attention: A Double-Blind, Placebo-Controlled, Crossover Pilot Study Cannabis. 2023
Found myrcene alone did not significantly impair simulated driving performance.
- 10
do Vale TG, et al. Central effects of citral, myrcene and limonene, constituents of essential oil chemotypes from Lippia alba (Mill.) n.e. Brown Phytomedicine. 2002
Demonstrated dose-dependent sedative and motor-relaxant effects of myrcene in mice.
- 11
Lorenzetti BB, et al. Myrcene mimics the peripheral analgesic activity of lemongrass tea Journal of Ethnopharmacology. 1991
Found peripheral analgesic activity in animal models.
- 12
Liktor-Busa E, et al. Analgesic Potential of Terpenes Derived from Cannabis sativa Pharmacological Reviews. 2021
Comprehensive review of cannabis terpene analgesic effects including myrcene.
- 13
Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish Journal of the American Chemical Society. 1964. doi:10.1021/ja01062a046
Landmark paper first identifying and synthesizing THC.
- 14
Whiting PF, et al. Cannabinoids for medical use: A systematic review and meta-analysis JAMA. 2015
Comprehensive review finding moderate evidence for chronic pain.
- 15
Aviram J, Samuelly-Leichtag G. Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Pain Physician. 2017
Systematic review of clinical trials for neuropathic pain.
- 16
Lutge EE, et al. The medical use of cannabis for reducing morbidity and mortality in patients with HIV/AIDS Cochrane Database of Systematic Reviews. 2013
Systematic review of cannabis for HIV/AIDS symptoms including appetite.
- 17
Smith LA, et al. Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy Cochrane Database of Systematic Reviews. 2015
High-quality evidence for CINV efficacy.
- 18
Kesner AJ, Lovinger DM. Cannabinoids, Endocannabinoids and Sleep Frontiers in Molecular Neuroscience. 2020
Review of THC effects on sleep architecture.
- 19
Novotna A, et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols (Sativex), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis European Journal of Neurology. 2011
Phase III trial showing efficacy for MS spasticity.
- 20
Silvestro S, et al. Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease Molecules. 2020
Comprehensive review of CBD's therapeutic applications and molecular targets.
- 21
Thiele EA, et al. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial Lancet. 2018
Phase III trial leading to FDA approval of Epidiolex.
- 22
Devinsky O, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial Lancet Neurology. 2016
Open-label trial showing 36.5% reduction in seizures.
- 23
Shannon S, et al. Cannabidiol in anxiety and sleep: A large case series Permanente Journal. 2019
79.2% of patients reported reduced anxiety within first month.
- 24
Bergamaschi MM, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients Neuropsychopharmacology. 2011
CBD reduced anxiety in simulated public speaking test.
- 25
Burstein S. Cannabidiol (CBD) and its analogs: a review of their effects on inflammation Bioorganic & Medicinal Chemistry. 2015
Review of CBD's anti-inflammatory mechanisms.
- 26
Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series Permanente Journal. 2019
66.7% of patients reported improved sleep in this anxiety and sleep study.
- 27
Urits I, et al. Use of cannabidiol (CBD) for the treatment of chronic pain Best Practice & Research Clinical Anaesthesiology. 2020
Comprehensive review of CBD for chronic pain management.
Research Verification
All citations link directly to PubMed or the original source. You can verify any claim by clicking the reference link. Learn more about how we research.
Frequently Asked Questions
What are the effects of J1?
J1 is known for producing relaxed, happy, euphoric effects. As a hybrid sativa, it's typically best suited for evening use.
What conditions might J1 help with?
J1 is commonly used by patients seeking relief from stress, anxiety, chronic pain. Always consult with a healthcare provider before using cannabis for medical purposes.
How strong is J1?
J1 is considered moderately potent with THC levels typically ranging from 18-24%. New users should approach with caution and start with a low dose.
What does J1 taste and smell like?
J1 features earthy, sweet, herbal flavors with a earthy, sweet, pungent aroma. Its unique terpene combination creates a memorable sensory experience.
What are the side effects of J1?
Common side effects include dry mouth, dry eyes. Staying hydrated and starting with a low dose can help minimize these effects.
Quick Facts
- Type
- Hybrid (Sativa-leaning)
- Genetics
- Skunk #1 x Jack Herer
- Genetic Family
- Skunk Family
- Best Time of Use
- Evening
- Availability
- rare
- Grow Difficulty
- moderate
- Experience Level
- Experienced Users
Dominant Terpene
Terpinolene
Fresh, piney, floral, with citrus and herbal notes
Want to try J1? Get your medical marijuana card today.
Get Your CardRelated by Genetics
Educational Information
This content is for educational purposes only and is not medical advice. Consult a healthcare provider before using cannabis products.
Strain Variability
Profiles vary between batches, growers, and growing conditions. Always check lab test results for the specific product you're purchasing.
Beyond Indica/Sativa
Effects are better predicted by cannabinoid and terpene profiles than strain classification. Focus on the chemistry, not the label.
Understanding Therapeutic Profiles
Learn how terpenes and cannabinoids work together to create each strain's unique effects and therapeutic potential through the entourage effect.
Learn About Therapeutic Profiles